While most studies have observed an increase in DRP1 expression/GTPase activity in post-mortem AD brains compared to controls (Manczak et al., 2011), decreases have also been reported (Wang et al., 2009), which may reflect differences in brain region, disease stage and/or pathological mechanism (Bera et al., 2022). This evidence concerns the gene DNM1L and Alzheimer disease.